Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 30 · below the Ichimoku cloud · RSI 43 · MACD above its signal · 4% above its 52-week low
None of the 29 investors followed here reported a position in 1858.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 1858.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Dec 30, 2025 | Shi (Chunbao)Director (Executive) | — | 732.8K | — |
| Dec 30, 2024 | Shi (Chunbao)Director (Executive) | — | 1.48M | — |
| Sep 2, 2024 | Shi (Chunbao)Director (Executive) | Acquisition at price 0.89 per share. | 790.8K | $706.77K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.5 | -4.5 | -3.2 | -19.5 | -10.3 | -9.9 | 6.7 | -10.2 | -4.1 | -5.9 | −50.4% | ||
| 2025 | 0.0 | 2.0 | 7.3 | -0.2 | 17.7 | 11.7 | 29.9 | -6.6 | 5.1 | 21.1 | -11.3 | -11.5 | +74.0% |
| 2024 | -27.0 | 8.9 | -5.1 | 23.4 | -18.7 | -8.7 | -5.3 | -12.3 | 30.2 | -14.6 | 5.4 | 1.9 | −31.5% |
| 2023 | 23.4 | 5.3 | -8.5 | 5.4 | -24.7 | 0.9 | -1.3 | -11.6 | -7.8 | 18.0 | -6.4 | -7.7 | −21.9% |
| 2022 | -22.1 | -9.3 | -12.0 | -1.3 | -7.4 | 56.3 | -9.1 | -6.4 | 3.3 | 1.7 | 18.4 | 11.9 | +5.4% |
| 2021 | -4.3 | -8.0 | -3.7 | 26.9 | 18.6 | -7.0 | -19.8 | -6.2 | -14.8 | 9.5 | 0.4 | -17.5 | −31.0% |
| 2020 | 21.6 | 40.2 | 24.5 | 12.5 | 13.0 | 6.7 | -13.3 | -3.3 | -15.9 | -13.8 | -37.8 | 9.9 | +19.7% |
| 2019 | 19.1 | 9.8 | 25.5 | 1.5 | -7.7 | -1.9 | 23.3 | 40.5 | 41.6 | 21.5 | 2.5 | -5.2 | +337.7% |
| 2018 | 10.4 | 7.4 | 2.7 | -2.9 | 7.7 | 14.4 | 14.5 | 21.8 | 0.4 | -9.8 | 6.7 | -17.5 | +61.9% |
| 2017 | -0.6 | -1.6 | 0.2 | 5.4 | 0.2 | 0.3 | -0.2 | -6.3 | -3.9 | 1.5 | -3.4 | 12.7 | +3.0% |
| 2016 | -10.1 | 0.9 | -0.6 | -0.2 | -0.3 | -2.5 | 0.5 | 0.8 | 7.3 | 2.1 | -2.7 | -7.0 | −12.2% |
| 2015 | 5.8 | 7.9 | -17.7 | -20.0 | -6.0 | 9.8 | 5.6 | 4.2 | 7.5 | −8.1% |
Buy / hold / sell counts
Beijing Chunlizhengda Medical Instruments Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of surgical implants, instruments, and related products in the People's Republic of China and internationally. The company offers orthopedic medical devices and tissue repair products, including spine, trauma, joint, sports medicine, and bone repair material implants; surgical instrumentation products; platelet-rich plasma preparation kits; and closed wound negative pressure drainage kits. It also provides surgical robots; joint, spinal, sports medicine, trauma, oral care, and endoscopic products; orthopedic power products; and platelet-rich plasma preparation system products, as well as alloy materials and surgical powering equipment. The company exports its products to approximately 68 countries. The company was formerly known as Chunli Limited and changed its name to Beijing Chunlizhengda Medical Instruments Co., Ltd. in September 2010. Beijing Chunlizhengda Medical Instruments Co., Ltd. was incorporated in 1998 and is headquartered in Beijing, China.
No recent headlines.